Inside Germany’s biotech capital infrastructure and innovation engine

About this episode

The episode discusses Germany's biotech landscape and the necessary shifts for European companies to scale globally.

In this episode of Denatured, as part of our series of the European life science investment ecosystem, you'll be hearing from Regina Hodits, managing director at Angelini Ventures and Sofia Ioannidou, VC partner at Andera Life Sciences. They examine Germany’s biotech and life sciences landscape, focusing on the scientific, infrastructure and policy shifts required to enable European companies to scale globally while remaining anchored in Europe. Host ⁠Jennifer C. Smith-Parker , Director of Insights, BioSpace Guests Regina Hodits , Managing Director, Angelini Ventures Sofia Ioannidou , VC Partner, Andera Life Sciences Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.

People in this episode

Host: Jennifer C. Smith-Parker

Guests: Regina Hodits, Sofia Ioannidou

Topics covered

• biotech
• life sciences
• investment ecosystem
• infrastructure
• innovation
• policy shifts

Keywords

• biotech
• life sciences
• Germany
• investment
• infrastructure
• innovation
• policy

Mentioned in this episode

Organizations: Angelini Ventures, Andera Life Sciences

Places: Germany, Europe

More episodes of BioSpace

• Portugal, Spain and the new biotech frontier · June 10, 2026 · 21 min
• Lilly tees off with Novo at ADA, GSK’s $10.6B deal, FDA reform continues in Makary’s absence · June 10, 2026 · 25 min
• Rethinking hair loss treatment · June 3, 2026 · 22 min
• ASCO wins from RevMed, Akeso/Summit, more; plus more Lilly and more China; ADA on deck · June 3, 2026 · 27 min
• France’s biotech ecosystem: science, capital and scale · May 28, 2026 · 21 min
• Lilly wheels and deals, Moderna gets boost on hantavirus scare, ASCO excitement builds · May 27, 2026 · 25 min